financetom
Business
financetom
/
Business
/
QuickLogic Q3 revenue down nearly 52%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
QuickLogic Q3 revenue down nearly 52%
Nov 11, 2025 1:57 PM

Overview

* QuickLogic ( QUIK ) fiscal Q3 revenue slightly missed analyst expectations, declining 51.8% yr/yr

* Adjusted EPS for fiscal Q3 beats consensus despite revenue decline

* Company highlights new eFPGA contract and defense market expansion

Outlook

* Company anticipates fourth-quarter revenue growth from USG Strategic Radiation Hardened FPGA Program

* QuickLogic ( QUIK ) expects orders for SRH FPGA Dev Kit and new eFPGA Hard IP contracts

Result Drivers

* NEW CONTRACT - QuickLogic ( QUIK ) won a $1 mln eFPGA Hard IP contract for a high-performance data-center ASIC, expanding commercial market success

* DEFENSE EXPANSION - Co expanded involvement with Defense Industrial Base entity specializing in cybersecurity for weapons systems

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Slight $2.03 $2.05

Revenue Miss* mln mln (2

Analysts

)

Q3 Beat -$0.19 -$0.21

Adjusted (2

loss per Analysts

share )

Q3 Net -$4.007

loss mln

Q3 $3.46

Operatin mln

g

Expenses

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the semiconductors peer group is "buy"

* Wall Street's median 12-month price target for Quicklogic Corp ( QUIK ) is $7.98, about 9.3% above its November 10 closing price of $7.23

* The stock recently traded at 2,884 times the next 12-month earnings vs. a P/E of 16 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Keurig Dr Pepper CEO Reveals What's Next After Raising Sales Outlook
Keurig Dr Pepper CEO Reveals What's Next After Raising Sales Outlook
Oct 27, 2025
Keurig Dr Pepper Inc. ( KDP ) shares rose Monday following the announcement of its financial results for the third quarter of fiscal 2025. The company exceeded consensus expectations on net sales and subsequently revised its full-year sales guidance upward. Financial Highlights The company reported adjusted earnings per share (EPS) of 54 cents, consistent with the analyst consensus estimate. Quarterly...
Eli Lilly Says Omvoh Shows Early, Sustained Improvement in Bowel Urgency in Ulcerative Colitis Patients
Eli Lilly Says Omvoh Shows Early, Sustained Improvement in Bowel Urgency in Ulcerative Colitis Patients
Oct 27, 2025
07:37 AM EDT, 10/27/2025 (MT Newswires) -- Eli Lilly ( LLY ) said Monday that Omvoh-treated patients with moderately to severely active ulcerative colitis saw early improvements in bowel urgency severity, frequency and stool deferral time by week 12, with the results continuing to improve through 28 weeks. Results from a Phase 3b trial showed that bowel urgency severity was...
Albemarle to divest Ketjen control, Eurecat stake in $660 million deal
Albemarle to divest Ketjen control, Eurecat stake in $660 million deal
Oct 27, 2025
(Reuters) -Albemarle said on Monday it will sell a 51% stake in its refining catalyst solutions business, Ketjen, to private equity firm KPS Capital Partners, and divest its 50% interest in the Eurecat joint venture to France's Axens SA, in deals worth about $660 million. Albemarle, one of the world's largest lithium producers, said it would use the proceeds for...
Intellia pauses late-stage trials of gene-editing treatment after serious liver event
Intellia pauses late-stage trials of gene-editing treatment after serious liver event
Oct 27, 2025
Oct 27 (Reuters) - Intellia Therapeutics ( NTLA ) said on Monday it has temporarily stopped dosing and screening patients in two late-stage studies of its one-time gene-editing treatment for a heart condition after a patient experienced a serious liver problem. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved